Head-to-head evidence
Diastat vs Diazepam (Libervant)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Diastat
Marketed by Bausch Health
NCT03953820 · Phase 1/2 · completed
The study randomized participants to treatment sequences and used Diastat as an active comparator, but it was open-label and small, with 31 randomized participants. Its primary endpoints were pharmacokinetic measures rather than clinical seizure outcomes, and the registry does not clearly report whether the primary comparison met its prespecified statistical criteria.
Diazepam (Libervant)
Marketed by Aquestive Therapeutics, Inc.
NCT03428360 · Phase 3 · completed
The study treated 130 participants with diazepam buccal film in a single open-label group, without randomization, blinding, or a control arm. Its primary outcomes were safety event counts rather than a controlled clinical comparison, so the findings cannot establish comparative treatment effectiveness.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diastat's landscape · Diazepam (Libervant)'s landscape